For companies with aggregated annual turnover below $20 million, cash refunds from the tax offset will be capped at $4 million per annum.
In addition, refundable R&D tax offsets from R&D expenditure on clinical trials will not count towards the cap.
Speaking to Accountants Daily, Thomson Reuters tax consultant, Terry Hayes, said the most contentious parts of the R&D tax overhaul are to do with the caps.
“I think the $4 million cap has caused a bit of a stir,” he said. “The caps were originally suggested to be at $2 million. Now they're $4 million, so they've doubled them, which I think is a good thing.
“But I think other companies, particularly those on the medical and pharmaceutical side, probably would not be overly warm towards that cap.”
As for why the cap is being put in place, Mr Hayes believes the government figures that it needs to try and take control of the incentive, and make sure that the expenditure is being made for the right purposes.
Regardless, he said the caps will cause a few problems for businesses.
“In simple terms, I guess the cap could’ve been higher than they set it,” Mr Hayes said.
“The payments are trying to cause companies to spend a certain amount before they get the R&D tax offset, but I think a lot of companies might just say the cap shouldn't have been done.”
The not-to-be-missed Accountants Daily Strategy Day will travel through Melbourne and Sydney in August to equip accounting professionals with the latest industry updates and tips for modern practice management as well as the latest cutting-edge technology, processes, strategies and trends shaping the future of accounting. Visit the website for more information: www.accountantsdaily.com.au/strategy-day